Levy J V
FEBS Lett. 1983 Apr 18;154(2):262-4. doi: 10.1016/0014-5793(83)80161-6.
Three calmodulin (CM) antagonists W-7, W-5 and trifluoperazine (TFP) were tested for ability to prevent aggregation of human, guinea pig, and rabbit platelets induced by 7.88 microM PAF. The naphthalene sulfonamide derivatives, W-7 and W-5, were active in all species, W-5 being 1,5--5.7-times less potent than W-7, in accordance with W-5 being a weaker CM inhibitor. ED50-Values for TFP were 155, 160 and 255 microM for rabbit, human and guinea pig platelets, respectively. Results are consistent with the notion that some substances antagonizing CM may inhibit PAF aggregation effects. W-7 is most effective on human platelets (ED50 51.5 microM). High concentrations of TFP required to antagonize PAF-induced aggregation cautions against ascribing its effects solely to an inhibitory effect on CM.
测试了三种钙调蛋白(CM)拮抗剂W-7、W-5和三氟拉嗪(TFP)预防7.88微摩尔/升血小板活化因子(PAF)诱导的人、豚鼠和兔血小板聚集的能力。萘磺酰胺衍生物W-7和W-5在所有物种中均有活性,W-5的效力比W-7低1.5至5.7倍,这与W-5是一种较弱的CM抑制剂一致。TFP对兔、人及豚鼠血小板的半数有效剂量(ED50)分别为155、160和255微摩尔/升。结果与某些拮抗CM的物质可能抑制PAF聚集作用的观点一致。W-7对人血小板最有效(ED50为51.5微摩尔/升)。拮抗PAF诱导的聚集所需的高浓度TFP提醒人们不要将其作用仅仅归因于对CM的抑制作用。